1.	Azacitidine and MS-275 in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: JHOC-J0658, CDR0000504083, U01CA070095, P30CA006973, JHOC-J0658, J0658, 7759, NCT00387465
2.	Interleukin 2, Aldesleukin and Entinostat for Kidney Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: I 145208, NCT01038778
3.	Phase I/II Study of Entinostat and Lapatinib Ditosylate in Patients With HER2-Positive, Locally Recurrent or Distant Relapsed, Metastatic Breast Cancer Who Failed Trastuzumab Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: MDA-2010-0842, 2010-0842, 8871, NCT01434303
4.	Phase II Randomized Study of Azacitidine With Versus Without Entinostat in Patients With Treatment- or Non-Treatment-Induced Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia With Multilineage Dysplasia Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E1905, E1905, NCT00313586
5.	Trial of Adjuvant Combined Epigenetic Therapy With 5-azacitidine and Entinostat in Resected Stage I Non-small Cell Lung Cancer Versus Standard Care Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: J1037 (NCI 8311), NA_00038631, NCT01207726
6.	Phase II Pilot Study of Entinostat and Anastrozole or Tamoxifen in Women With Resectable Triple-Negative Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: UCCRC-IL-057, IL-057, 8597, NCT01234532
7.	A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML) Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 60 and over Sponsor: Other Protocol IDs: J1093, NCT01305499
8.	Phase II Study of Azacitidine and Entinostat in Patients With Advanced Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: MAYO-MC1035, MC1035, 8822, NCT01349959
9.	Phase I Study of Entinostat and Clofarabine in Patients With Newly Diagnosed or Relapsed or Refractory Philadelphia Chromosome-Negative, Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 21 and over Sponsor: NCI Protocol IDs: JHOC-MD017, SKCCC-MD017, 8298, NCT01132573
10.	Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 90 Sponsor: Pharmaceutical / Industry Protocol IDs: SNDX-275-0110, NCT01594398